Genetic, molecular anomalies determine RCC therapy

Management of kidney cancer is advancing on several fronts, and this theme of continued progress is well illustrated by research being presented at the AUA annual meeting, said Robert C. Flanigan, MD.

Related Videos

Related Content

Advertisement

July 16th 2025

Meeting with FDA paves way for phase 3 trial of Alpha1H in NMIBC

Hannah Clarke

Alpha1H was granted a fast track designation in November 2023.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 15th 2025

Carotuximab plus apalutamide demonstrates safety, tolerability in mCRPC

Hannah Clarke

The company said it plans to report interim efficacy data from the trial in September 2025.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 14th 2025

Elevated blood sugar linked with negative changes in sexual functioning

Hannah Clarke

In healthy aging men without developing diabetes mellitus, modest increases in HbA1c were linked with declines in sperm motility and erectile function.

July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.

Related Content

Advertisement

July 16th 2025

Meeting with FDA paves way for phase 3 trial of Alpha1H in NMIBC

Hannah Clarke

Alpha1H was granted a fast track designation in November 2023.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 15th 2025

Carotuximab plus apalutamide demonstrates safety, tolerability in mCRPC

Hannah Clarke

The company said it plans to report interim efficacy data from the trial in September 2025.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 14th 2025

Elevated blood sugar linked with negative changes in sexual functioning

Hannah Clarke

In healthy aging men without developing diabetes mellitus, modest increases in HbA1c were linked with declines in sperm motility and erectile function.

July 10th 2025

FDA grants breakthrough device designation for ArteraAI Prostate tool

Benjamin P. Saylor Hannah Clarke

“This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.